Table 9.
The KEGG pathway enrichment analysis of some significant membrane protein.
| KEGG pathway | P value | Predicted protein of SARS-CoV-2 |
|---|---|---|
| Proteosome/Protolysis | 6.9E−2 | VTI1A, ZFPL1, MYRF, MGAT2, CLCA4, PRSS8, |
| ST14, TRHDE, MEP1A, MMP24, PSMC5, PSMD14, | ||
| PSME1, PSMB1, PSMA2, OLR1, POMP | ||
| Ubiquitin mediated proteolysis | 6.9E−2 | FBXW11, HERC2, HERC4, HERC1, WWP1, MGRN1, |
| NEDD4, UBE3A, UBA2, UBE2K, UBE2G1, UBE2E1, | ||
| UBE2D2, NEDD4L | ||
| Clathrin dependent endocytosis | 2.2E−6 | AP2A2, DNM2, APLP1, EPS15, EPN1, EPN2, |
| LDLR, LY75, MRC2, SNX5 | ||
| Endocytosis | 1.2E−8 | FGFR4, IGF1R, IL2RA, PSD2, TPCN2, ARF1, |
| ARAP2, CLTA, CYTH1, RAB11, FIP1, RAB11A, | ||
| SNF8, VPS29, VPS37B, WWP1, ARPC1B, | ||
| GITI, ARPC2, CAPZB, CHMP5, HLA-F, NEDD4, | ||
| PSD2, PDCD6IP, CHMP2A | ||
| Glycosaminoglycan biosynthesis | 2.5E−3 | NDST1, NDST2, NDST3, NDST4, CHST1, CHST2, |
| CHST3, CHST4, CHST17, CHPF2 GLCE, EXT1, | ||
| EXTL1, EXTL2, GLCE, XYLT2, XYLT1 | ||
| Cytokine mediated signaling pathway | 2.6E−5 | BCL2, CD226, CD27, CD276, CD28, FCER2, |
| KIT, LRP8, MCL1, NFAM1, TRIL, VTCN1, | ||
| EDA, EREG, ICAM1, PTPRN, STX1A, STX3 | ||
| Cytokine–cytokine receptor interaction | 7.0E−2 | CD70, ACVR1, AMHR2, BMPR2, CSF1, CRLF2, |
| EDAR, EPOR, GHR, L1R2, IL2RA, IL21R, | ||
| IL23R, IL5RA, IL9R, LEPR, OSMR, PRLR | ||
| T cell receptor signaling pathway | 8.0E−1 | CD8A, CD226, CD276, CD28, CD3D, CD3G, |
| CD8A, CD8B, CTLA4, ICOS, LAT, | ||
| Leukocyte transendothelial migration | 3.9E−3 | THY1, ESAM, ICAM1, JAM2, JAM3, VCAM1 |
| MAPK signaling pathway | 8.9E−4 | FLT3, EPHA8, KIT, MET, AREG, CSF1, |
| EREG, ERBB2, ERBB3, ERBB4, FGFR4, FLT3, | ||
| IGF1R, INSR, NTRK1, NTRK2, PTPRR, TGFA, EPHA2 | ||
| JAK-STAT signaling pathway | 2.9E−2 | KIT, MCL1, CRLF2, EGF, EPOR, GHR |
| , IL2RA, IL21R, IL5RA, IL9R, LEPR, OSMR, | ||
| PRLR, BCL2, | ||
| EGFR tyrosine kinase inhibitor | 8.4E−3 | IGF1R, EGF, ERBB2, ERBB3, IGF1R, NRG1, |
| NRG2, TGFA, BCL2, MET, BAX | ||
| Unfolded protein response | 1.4E−2 | VAPB, XBP1, ATF6B, CREB3, EDEM1 |
| Protein processing in | 1.0E−2 | EDEM1, XBP1, ATF6B, VCP, HSPA5, PDIA6, |
| LMAN1, PREB, RRBP1, | ||
| Endoplasmic reticulum | DNAJB1, SIL1, SEC61G, XBP1, DERL2, PRKCSH, | |
| CAPN1, CALR, CKAP4, DERL1, EIF2AK1, HSP90AB1, | ||
| NFE2L2, PREB, PDIA3, CANX | ||
| Viral carcinogenesis | 6.0E−2 | BAX, BAK1, DCC, REB3, BAD, CREBBP, J |
| UN, KRAS, RASA2, SP100, TRADD, CCND1, | ||
| CCND3, CDK2, CDK6, CDKN1B, GTF2A2, MAPK3 | ||
| SYK, NFKB2, CDKN1A | ||
| Viral myocarditis | 1.4E−2 | DAG1, ICAM1, SGCA, SGCB, SGCD, ICAM1, |
| HLA-F, SGCC, CD28, CD55, CXADR, CYCS | ||
| Antigen processing and presentation | 1.1E−4 | CD8A, CD8B, CD74, HLA-DRA, CD1B, LGMN, |
| HLA-F, | ||
| Carbon metabolism | 9.4E−2 | KIT, MET, FLT3, NTRK1, NTRK3, RET, |
| RAF1, ERBB2 | ||
| Biosynthesis of antibiotics | 3.2E−2 | ACLY, SQLE, NME2, ACAT1, CDC42, FDFT1, |
| FNTA, FMO1, FMO3, FMO4, FMO5, UGT1A1, | ||
| GMPS, MGST1, PGP |